Molecular monitoring of plasmodium falciparum drug susceptibility at the time of the introduction of artemisinin-based combination therapy in Yaoundé, Cameroon: Implications for the future

Malaria Journal

Volumn 11, Issue , 2012, Pages

  Menard, Sandie ^a   Morlais, Isabelle ^b,c   Tahar, Rachida ^c,d   Sayang, Collins ^c,e   Mayengue, Pembe Issamou ^f   Iriart, Xavier ^a   Benoit Vical, Françoise ^f   Lemen, Brigitte ^g   Magnaval, Jean François ^h   Awono Ambene, Parfait ^c   Basco, Leonardo K ^c,i   Berry, Antoine ^a  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^c Organisation de Coordination pour la Lutte contre les Endemies en Afrique Centrale Cameroon   (Cameroon)

^d INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^e AIX MARSEILLE UNIVERSITY   (France)

^f LCC LABORATOIRE DE CHIMIE DE COORDINATION   (France)

^g Centre d'Animation Sociale et Sanitaire (CASS)   (Cameroon)

^h UNIVERSITÉ DE TOULOUSE   (France)

ⁱ CNRS   (France)

Author keywords

Cameroon; LNA probes; Malaria; pfcrt; pfmdr1; pfmdr1 copy number; Resistance

Indexed keywords

AMODIAQUINE PLUS ARTESUNATE; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; CARRIER PROTEIN; MDR1 PROTEIN, PLASMODIUM FALCIPARUM; MULTIDRUG RESISTANCE PROTEIN; PFCRT PROTEIN, PLASMODIUM FALCIPARUM; PROTOZOAL DNA; PROTOZOAL PROTEIN;

ADOLESCENT; ADULT; ANTIMALARIAL DRUG SUSCEPTIBILITY; ARTICLE; CAMEROON; CHILD; CODON; CONTROLLED STUDY; GENE DOSAGE; GENE DUPLICATION; GENE FREQUENCY; GENE MUTATION; GENOTYPE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALARIA CONTROL; MALARIA FALCIPARUM; NONHUMAN; PFCRT GENE; PFMDR1 GENE; PLASMODIUM FALCIPARUM; PRESCHOOL CHILD; REAL TIME POLYMERASE CHAIN REACTION; SCHOOL CHILD; DRUG COMBINATION; DRUG EFFECT; DRUG RESISTANCE; FEMALE; GENETICS; MALE; METHODOLOGY; MIDDLE AGED; MISSENSE MUTATION; NEWBORN; PARASITOLOGY; PREVALENCE; SENTINEL SURVEILLANCE;

ADOLESCENT; ADULT; ANTIMALARIALS; ARTEMISININS; CAMEROON; CHILD; CHILD, PRESCHOOL; DNA, PROTOZOAN; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HUMANS; INFANT; INFANT, NEWBORN; MALARIA, FALCIPARUM; MALE; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; MUTATION, MISSENSE; PLASMODIUM FALCIPARUM; PREVALENCE; PROTOZOAN PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; SENTINEL SURVEILLANCE; YOUNG ADULT;

EID: 84859643462     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-11-113     Document Type: Article

References (61)

1. World Malaria Report 2008. WHO, 2008 http://www.who.int/malaria/ publications/atoz/9789241563697/en/index.html
2. Treatment of malaria from monotherapy to artemisinin-based combination therapy by health professionals in urban health facilities in Yaounde, central province, Cameroon. Sayang C, Gausseres M, Vernazza-Licht N, Malvy D, Bley D, Millet P, Malar J 2009 8 176 10.1186/1475-2875-8-176 19640292
3. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Price RN, Uhlemann AC, Brockman A, McGready R, Ashley E, Phaipun L, Patel R, Laing K, Looareesuwan S, White NJ, Nosten F, Krishna S, Lancet 2004 364 438 447 10.1016/S0140-6736(04)16767-6 15288742 (Pubitemid 39036891)
4. Decreasing pfmdr1 copy number in Plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin. Sidhu AB, Uhlemann AC, Valderramos SG, Valderramos JC, Krishna S, Fidock DA, J Infect Dis 2006 194 528 535 10.1086/507115 16845638 (Pubitemid 44162666)
5. Pfmdr1 copy number and arteminisin derivatives combination therapy failure in falciparum malaria in Cambodia. Lim P, Alker AP, Khim N, Shah NK, Incardona S, Doung S, Yi P, Bouth DM, Bouchier C, Puijalon OM, Meshnick SR, Wongsrichanalai C, Fandeur T, Le Bras J, Ringwald P, Ariey F, Malar J 2009 8 11 10.1186/1475-2875-8-11 19138391
6. Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. Carrara VI, Zwang J, Ashley EA, Price RN, Stepniewska K, Barends M, Brockman A, Anderson T, McGready R, Phaiphun L, Proux S, Van Vugt M, Hutagalung R, Maung Lwin K, Pyae Phyo A, Preechapornkul P, Imwong M, Pukrittayakamee S, Singhasivanon P, White NJ, Nosten F, PLoS One 2009 4 4551 10.1371/journal.pone. 0004551 19234601
7. Genomic analysis of mefloquine-resistant Plasmodium falciparum. Begum K, Kim HS, Okuda Y, Wataya Y, Kimura M, Huruta T, Nucleic Acids Res Suppl 2002 2 223 224 12903186
8. Artemisinin-induced dormancy in Plasmodium falciparum: duration, recovery rates, and implications in treatment failure. Teuscher F, Gatton ML, Chen N, Peters J, Kyle DE, Cheng Q, J Infect Dis 2010 202 1362 1368 10.1086/656476 20863228
9. Increased pfmdr1 Copy Number and Sequence Polymorphisms in Plasmodium falciparum Isolates from Sudanese Malaria Patients Treated with Artemether-Lumefantrine. Gadalla NB, Adam I, Elzaki SE, Bashir S, Mukhtar I, Oguike M, Gadalla A, Mansour F, Warhurst D, El-Sayed BB, Sutherland CJ, Antimicrob Agents Chemother 2011 55 5408 5411 10.1128/AAC.05102-11 21896916
10. pfmdr1 mutations contribute to quinine resistance and enhance mefloquine and artemisinin sensitivity in Plasmodium falciparum. Sidhu AB, Valderramos SG, Fidock DA, Mol Microbiol 2005 57 913 926 10.1111/j.1365-2958.2005.04729.x 16091034 (Pubitemid 41139856)
11. The tyrosine-86 allele of the pfmdr1 gene of Plasmodium falciparum is associated with increased sensitivity to the anti-malarials mefloquine and artemisinin. Duraisingh MT, Jones P, Sambou I, von Seidlein L, Pinder M, Warhurst DC, Mol Biochem Parasitol 2000 108 13 23 10.1016/S0166-6851(00)00201-2 10802315 (Pubitemid 30236312)
12. Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania. Martensson A, Stromberg J, Sisowath C, Msellem MI, Gil JP, Montgomery SM, Olliaro P, Ali AS, Bjorkman A, Clin Infect Dis 2005 41 1079 1086 10.1086/444460 16163624 (Pubitemid 41429468)
13. Prolonged selection of pfmdr1 polymorphisms after treatment of falciparum malaria with artemether-lumefantrine in Uganda. Baliraine FN, Rosenthal PJ, J Infect Dis 2011 204 1120 1124 10.1093/infdis/jir486 21881128
14. In vivo selection of Plasmodium falciparum pfmdr1 86 N coding alleles by artemether-lumefantrine (Coartem). Sisowath C, Stromberg J, Martensson A, Msellem M, Obondo C, Bjorkman A, Gil JP, J Infect Dis 2005 191 1014 1017 10.1086/427997 15717281 (Pubitemid 40349821)
15. Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine- pyrimethamine but not dihydroartemisinin-piperaquine in Burkina Faso. Some AF, Sere YY, Dokomajilar C, Zongo I, Rouamba N, Greenhouse B, Ouedraogo JB, Rosenthal PJ, Antimicrob Agents Chemother 2010 54 1949 1954 10.1128/AAC.01413-09 20231394
16. Short report: association between chloroquine and amodiaquine resistance and allelic variation in the Plasmodium falciparum multiple drug resistance 1 gene and the chloroquine resistance transporter gene in isolates from the upper Nile in southern Sudan. Ochong EO, van den Broek IV, Keus K, Nzila A, Am J Trop Med Hyg 2003 69 184 187 13677373
17. Amodiaquine resistant Plasmodium falciparum malaria in vivo is associated with selection of pfcrt 76T and pfmdr1 86Y. Holmgren G, Gil JP, Ferreira PM, Veiga MI, Obonyo CO, Bjorkman A, Infect Genet Evol 2006 6 309 314 10.1016/j.meegid.2005.09.001 16271310 (Pubitemid 43785813)
18. Association between mutations in Plasmodium falciparum chloroquine resistance transporter and P. falciparum multidrug resistance 1 genes and in vivo amodiaquine resistance in P. falciparum malaria-infected children in Nigeria. Happi CT, Gbotosho GO, Folarin OA, Bolaji OM, Sowunmi A, Kyle DE, Milhous W, Wirth DF, Oduola AM, Am J Trop Med Hyg 2006 75 155 161 16837724 (Pubitemid 351627586)
19. Chloroquine-resistance molecular markers (Pfcrt T76 and Pfmdr-1 Y86) and amodiaquine resistance in Burkina Faso. Tinto H, Guekoun L, Zongo I, Guiguemde RT, D'Alessandro U, Ouedraogo JB, Trop Med Int Health 2008 13 238 240 10.1111/j.1365-3156.2007.01995.x 18304270 (Pubitemid 351316975)
20. Efficacy, safety, and selection of molecular markers of drug resistance by two ACTs in Mali. Djimde AA, Fofana B, Sagara I, Sidibe B, Toure S, Dembele D, Dama S, Ouologuem D, Dicko A, Doumbo OK, Am J Trop Med Hyg 2008 78 455 461 18337343 (Pubitemid 351845197)
21. Selection of parasites with diminished drug susceptibility by amodiaquine-containing antimalarial regimens in Uganda. Nawaz F, Nsobya SL, Kiggundu M, Joloba M, Rosenthal PJ, J Infect Dis 2009 200 1650 1657 10.1086/647988 19905933
22. Occurrence of the Southeast Asian/South American SVMNT haplotype of the chloroquine-resistance transporter gene in Plasmodium falciparum in Tanzania. Alifrangis M, Dalgaard MB, Lusingu JP, Vestergaard LS, Staalsoe T, Jensen AT, Enevold A, Ronn AM, Khalil IF, Warhurst DC, Lemnge MM, Theander TG, Bygbjerg IC, J Infect Dis 2006 193 1738 1741 10.1086/504269 16703518 (Pubitemid 43839479)
23. Plasmodium falciparum isolates from Angola show the StctVMNT haplotype in the pfcrt gene. Gama BE, Pereira-Carvalho GA, Lutucuta Kosi FJ, Almeida de Oliveira NK, Fortes F, Rosenthal PJ, Daniel-Ribeiro CT, de Fatima Ferreira-da-Cruz M, Malar J 2010 9 174 10.1186/1475-2875-9-174 20565881
24. Protecting the malaria drug arsenal: halting the rise and spread of amodiaquine resistance by monitoring the pfcrt SVMNT type. Sa JM, Twu O, Malar J 2010 9 374 10.1186/1475-2875-9-374 21182787
25. Geographic patterns of Plasmodium falciparum drug resistance distinguished by differential responses to amodiaquine and chloroquine. Sa JM, Twu O, Hayton K, Reyes S, Fay MP, Ringwald P, Wellems TE, Proc Natl Acad Sci USA 2009 106 18883 18889 10.1073/pnas.0911317106 19884511
26. Molecular approaches to the spreading problem of drug resistant malaria. Plowe CV, Wellems TE, Adv Exp Med Biol 1995 390 197 209 8718614 (Pubitemid 126634682)
27. Plasmodium falciparum isolates with increased pfmdr1 copy number circulate in West Africa. Witkowski B, Nicolau ML, Soh PN, Iriart X, Menard S, Alvarez M, Marchou B, Magnaval JF, Benoit-Vical F, Berry A, Antimicrob Agents Chemother 2010 54 3049 3051 10.1128/AAC.00209-10 20404118
28. Detection by real-time PCR of the pfcrt T76 mutation, a molecular marker of chloroquine-resistant Plasmodium falciparum strains. Vessiere A, Berry A, Fabre R, Benoit-Vical F, Magnaval JF, Parasitol Res 2004 93 5 7 10.1007/s00436-004-1096-6 15029493 (Pubitemid 38797733)
29. African monkeys are infected by Plasmodium falciparum nonhuman primate-specific strains. Prugnolle F, Ollomo B, Durand P, Yalcindag E, Arnathau C, Elguero E, Berry A, Pourrut X, Gonzalez JP, Nkoghe D, Akiana J, Verrier D, Leroy E, Ayala FJ, Renaud F, Proc Natl Acad Sci USA 2011 108 11948 11953 10.1073/pnas.1109368108 21730135
30. The first analogues of LNA (locked nucleic acids): phosphorothioate-LNA and 2'-thio-LNA. Kumar R, Singh SK, Koshkin AA, Rajwanshi VK, Meldgaard M, Wengel J, Bioorg Med Chem Lett 1998 8 2219 2222 10.1016/S0960-894X(98)00366-7 9873516 (Pubitemid 28561609)
31. LNA-modified primers drastically improve hybridization to target RNA and reverse transcription. Fratczak A, Kierzek R, Kierzek E, Biochemistry 2009 48 514 516 10.1021/bi8021069 19119855
32. Real-time genotyping with oligonucleotide probes containing locked nucleic acids. Ugozzoli LA, Latorra D, Puckett R, Arar K, Hamby K, Anal Biochem 2004 324 143 152 10.1016/j.ab.2003.09.003 14654057 (Pubitemid 37491135)
33. Use of a locked-nucleic-acid oligomer in the clamped-probe assay for detection of a minority pfcrt K76T mutant population of Plasmodium falciparum. Senescau A, Berry A, Benoit-Vical F, Landt O, Fabre R, Lelievre J, Cassaing S, Magnaval JF, J Clin Microbiol 2005 43 3304 3308 10.1128/JCM.43.7.3304-3308.2005 16000452 (Pubitemid 40981340)
34. Identification of a mutant PfCRT-mediated chloroquine tolerance phenotype in Plasmodium falciparum. Valderramos SG, Valderramos JC, Musset L, Purcell LA, Mercereau-Puijalon O, Legrand E, Fidock DA, PLoS Pathog 2010 6 1000887 10.1371/journal.ppat.1000887 20485514
35. Country Health System Fact Sheet 2006, Cameroon. WHO, 2006 http://www.afro.who.int/en/cameroon/country-health-profile.html
36. Molecular epidemiology of malaria in Cameroon. XIII. Analysis of pfcrt mutations and in vitro chloroquine resistance. Basco LK, Am J Trop Med Hyg 2002 67 388 391 12455496 (Pubitemid 35303861)
37. Molecular epidemiology of malaria in Cameroon. X. Evaluation of pfmdr1 mutations as genetic markers for resistance to amino alcohols and artemisinin derivatives. Basco LK, Ringwald P, Am J Trop Med Hyg 2002 66 667 671 12224572 (Pubitemid 35005825)
38. Efficacy of amodiaquine, sulphadoxine-pyrimethamine and their combination for the treatment of uncomplicated Plasmodium falciparum malaria in children in Cameroon at the time of policy change to artemisinin-based combination therapy. Mbacham WF, Evehe MS, Netongo PM, Ateh IA, Mimche PN, Ajua A, Nji AM, Irenee D, Echouffo-Tcheugui JB, Tawe B, Hallett R, Roper C, Targett G, Greenwood B, Malar J 2010 9 34 10.1186/1475-2875-9-34 20105282
39. Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. Kublin JG, Cortese JF, Njunju EM, Mukadam RA, Wirima JJ, Kazembe PN, Djimde AA, Kouriba B, Taylor TE, Plowe CV, J Infect Dis 2003 187 1870 1875 10.1086/375419 12792863 (Pubitemid 36724485)
40. Recovery of chloroquine sensitivity and low prevalence of the Plasmodium falciparum chloroquine resistance transporter gene mutation K76T following the discontinuance of chloroquine use in Malawi. Mita T, Kaneko A, Lum JK, Bwijo B, Takechi M, Zungu IL, Tsukahara T, Tanabe K, Kobayakawa T, Bjorkman A, Am J Trop Med Hyg 2003 68 413 415 12875289 (Pubitemid 38230640)
41. Chloroquine resistance before and after its withdrawal in Kenya. Mwai L, Ochong E, Abdirahman A, Kiara SM, Ward S, Kokwaro G, Sasi P, Marsh K, Borrmann S, Mackinnon M, Nzila A, Malar J 2009 8 106 10.1186/1475-2875-8-106 19450282
42. Decreased prevalence of the Plasmodium falciparum chloroquine resistance transporter 76T marker associated with cessation of chloroquine use against P. falciparum malaria in Hainan, People's Republic of China. Wang X, Mu J, Li G, Chen P, Guo X, Fu L, Chen L, Su X, Wellems TE, Am J Trop Med Hyg 2005 72 410 414 15827277 (Pubitemid 41278849)
43. In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa. Sisowath C, Petersen I, Veiga MI, Martensson A, Premji Z, Bjorkman A, Fidock DA, Gil JP, J Infect Dis 2009 199 750 757 10.1086/596738 19210165
44. Molecular analysis of chloroquine resistance in Plasmodium falciparum in Yunnan Province, China. Yang Z, Zhang Z, Sun X, Wan W, Cui L, Zhang X, Zhong D, Yan G, Cui L, Trop Med Int Health 2007 12 1051 1060 10.1111/j.1365-3156.2007. 01882.x 17875016 (Pubitemid 47414938)
45. Increased prevalence of the Plasmodium falciparum pfmdr1 86N genotype among field isolates from Franceville, Gabon after replacement of chloroquine by artemether-lumefantrine and artesunate-mefloquine. Lekana-Douki JB, Dinzouna Boutamba SD, Zatra R, Zang Edou SE, Ekomy H, Bisvigou U, Toure-Ndouo FS, Infect Genet Evol 2011 11 512 517 10.1016/j.meegid.2011.01.003 21251998
46. Amodiaquine resistance is not related to rare findings of pfmdr1 gene amplifications in Kenya. Holmgren G, Bjorkman A, Gil JP, Trop Med Int Health 2006 11 1808 1812 10.1111/j.1365-3156.2006.01742.x 17176345 (Pubitemid 44813875)
47. Withdrawing antimalarial drugs: impact on parasite resistance and implications for malaria treatment policies. Laufer MK, Plowe CV, Drug Resist Updat 2004 7 279 288 10.1016/j.drup.2004.08.003 15533765 (Pubitemid 39469100)
48. Fitness of drug-resistant malaria parasites. Walliker D, Hunt P, Babiker H, Acta Trop 2005 94 251 259 10.1016/j.actatropica.2005.04.005 15845348 (Pubitemid 40723640)
49. Origin and dissemination of Plasmodium falciparum drug-resistance mutations in South America. Cortese JF, Caraballo A, Contreras CE, Plowe CV, J Infect Dis 2002 186 999 1006 10.1086/342946 12232841
50. Analysis of the pfcrt K76T mutation in Plasmodium falciparum isolates from the Amazon region of Brazil. Vieira PP, Das Gracas Alecrim M, Da Silva LH, Gonzalez-Jimenez I, Zalis MG, J Infect Dis 2001 183 1832 1833 10.1086/320739 11372042 (Pubitemid 32523252)
51. Characterization of Plasmodium falciparum isolated from the Amazon region of Brazil: evidence for quinine resistance. Zalis MG, Pang L, Silveira MS, Milhous WK, Wirth DF, Am J Trop Med Hyg 1998 58 630 637 9598453 (Pubitemid 28237263)
52. Discordant patterns of genetic variation at two chloroquine resistance loci in worldwide populations of the malaria parasite Plasmodium falciparum. Mehlotra RK, Mattera G, Bockarie MJ, Maguire JD, Baird JK, Sharma YD, Alifrangis M, Dorsey G, Rosenthal PJ, Fryauff DJ, Kazura JW, Stoneking M, Zimmerman PA, Antimicrob Agents Chemother 2008 52 2212 2222 10.1128/AAC.00089-08 18411325 (Pubitemid 351758561)
53. The role of pfmdr1 in Plasmodium falciparum tolerance to artemether-lumefantrine in Africa. Sisowath C, Ferreira PE, Bustamante LY, Dahlstrom S, Martensson A, Bjorkman A, Krishna S, Gil JP, Trop Med Int Health 2007 12 736 742 10.1111/j.1365-3156.2007.01843.x 17550470 (Pubitemid 46872790)
54. Parasites bearing a single copy of the multi-drug resistance gene (pfmdr-1) with wild-type SNPs predominate amongst Plasmodium falciparum isolates from Malawi. Nkhoma S, Nair S, Mukaka M, Molyneux ME, Ward SA, Anderson TJ, Acta Trop 2009 111 78 81 10.1016/j.actatropica.2009.01.011 19426667
55. No pfmdr1 amplifications in samples from Guinea-Bissau and Liberia collected between 1981 and 2004. Ursing J, Kofoed PE, Rombo L, Gil JP, J Infect Dis 2006 194 716 718 author reply 718-719 16897676 (Pubitemid 44297863)
56. Analysis of pfmdr1 and drug susceptibility in fresh isolates of Plasmodium falciparum from subsaharan Africa. Basco LK, Le Bras J, Rhoades Z, Wilson CM, Mol Biochem Parasitol 1995 74 157 166 10.1016/0166-6851(95)02492-1 8719157 (Pubitemid 26024474)
57. Amplification of Plasmodium falciparum multidrug resistance gene 1 in isolates from Gabon. Uhlemann AC, Ramharter M, Lell B, Kremsner PG, Krishna S, J Infect Dis 2005 192 1830 1835 10.1086/497337 16235185 (Pubitemid 41587837)
58. Pfmdr1 alleles and response to ultralow-dose mefloquine treatment in Gabonese patients. Mawili-Mboumba DP, Kun JF, Lell B, Kremsner PG, Ntoumi F, Antimicrob Agents Chemother 2002 46 166 170 10.1128/AAC.46.1.166-170.2002 11751128 (Pubitemid 34031619)
59. Arteflene compared with mefloquine for treating Plasmodium falciparum malaria in children. Radloff PD, Philipps J, Nkeyi M, Sturchler D, Mittelholzer ML, Kremsner PG, Am J Trop Med Hyg 1996 55 259 262 8842111 (Pubitemid 26321828)
60. Malaria chemotherapy trial at a minimal effective dose of mefloquine/sulfadoxine/pyrimethamine compared with equivalent doses of sulfadoxine/pyrimethamine or mefloquine alone. Lell B, Lehman LG, Schmidt-Ott JR, Sturchler D, Handschin J, Kremsner PG, Am J Trop Med Hyg 1998 58 619 624 9598451 (Pubitemid 28237261)
61. Antimalarial drugs: recent advances in molecular determinants of resistance and their clinical significance. Woodrow CJ, Krishna S, Cell Mol Life Sci 2006 63 1586 1596 10.1007/s00018-006-6071-1 16699808 (Pubitemid 44252173)